Sort
82,697 grants matching “vaccine development”
Natural infection of norovirus and sapovirus in a birth cohort in a Peruvian periurban community
$1,056,841Robert H Gilman · Johns Hopkins University · R01 · FY2019 · AI
Chicago Community-Acquired Pneumonia Consortium II
$1,056,782Richard G Wunderink · Northwestern University At Chicago · U18 · FY2011 · IP
Technology Component
$1,056,755John Barker Harley · Oklahoma Medical Research Foundation · U19 · FY2008 · AI
Prenatal Factors and Risk of Schizophrenia in a Finnish National Birth Cohort
$1,056,592Alan Stewart Brown · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · R01 · FY2008 · MH
Aurum Clinical Trials Unit
$1,056,434Gavin John Churchyard · Aurum Institute Npc · UM1 · FY2021 · AI
Development of Vaccines to Prevent Tuberculosis
$1,056,433Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Development of Pre-Erythrocytic Malaria Vaccines and antibodies
$1,056,433Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Development of Pre-Erythrocytic Malaria Vaccines and antibodies
$1,056,433Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Project 2 - Novel Therapeutics for Emerging Alphavirus
$1,056,208Daniel N Streblow · University Of Alabama At Birmingham · U19 · FY2019 · AI
ANTIGEN-SPECIFIC VACCINES FOR BREAST CANCER
$1,055,613Johns Hopkins University · U19 · FY2003 · CA
IGF::OT::IGF NIAID PRECLINICAL DEVELOPMENT SUPPORT - PERFORMANCE OF TOXICITY TESTING FOR HIV PROTEINS
$1,055,333Shqipe Courtis · Advanced Bioscience Laboratories, Inc. · N01 · FY2015 · AI
Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease
$1,055,169Jay Williams Hooper · Geneva Foundation · R01 · FY2018 · AI
Targeting mTOR to Enhance Immunogenicity and Efficacy of HIV Vaccines
$1,055,040Rafi Ahmed · Emory University · P01 · FY2011 · AI
Pathogenesis and countermeasures of poxviruses, hemorrhagic fever viruses, MERS
$1,054,912Peter Jahrling · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Monoclonal Antibodies in Biodefense: Ebola Viruses
$1,054,720Mapp Biopharmaceutical, Inc. · U01 · FY2005 · AI
Task X3: Evaluation of Clinical Samples from Influenza Clinical Trials
$1,054,656Carol Sabourin · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2020 · AI
HIV-1 Fusion Peptide-directed Vaccine Design Using Virus-like Particles
$1,054,497Rui Kong · Emory University · R01 · FY2023 · AI
Mechanism of action and therapeutic utility of stimulatory CpG oligonucleotides
$1,054,354Dennis Klinman · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Once Bitten: Acquisition of Malaria Adaptive Immunity (OBAMA - Immunity)
$1,054,247Wendy Prudhommeomeara · Duke University · R01 · FY2025 · AI
UPR/MDACC: Partnership for Excellence in Cancer Research (1 of 2)
$1,054,072Elizabeth L Travis · University Of Tx Md Anderson Can Ctr · U54 · FY2021 · CA
Immunity to Pneumonic Tularemia
$1,053,791Catharine Bosio · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Advanced Development of a Combined Shigella-ETEC Vaccine
$1,053,471Eileen M. Barry · University Of Maryland Baltimore · R01 · FY2023 · AI
Chicago Clinical Trials Unit
$1,053,181Chad J Achenbach · Northwestern University At Chicago · UM1 · FY2024 · AI
FURTHER DEVELOPMENT OF COLOVAC, A MULTI-ANTIGEN MULTI-PEPTIDE VACCINE, FOR COLON CANCER PREVENTION
$1,052,768Clinton Grubbs · University Of Alabama At Birmingham · N01 · FY2019 · CA
PATHOGENESIS AND PREVENTION OF AUTOIMMUNE DIABETES
$1,052,680Yale University · P01 · FY2000 · DK